ABSTRACT
INTRODUCTION

Mantle cell lymphoma (MCL) is aggressive B-cell lymphomas that
accounts for approximately 6-8% of Non-Hodgkin's Lymphomas and has distinct clinical and pathological features 1, 2 . The majority of patients present with advanced stage disease (Ann Arbor stages III/IV) at diagnosis, and more than 90% of patients have extranodal manifestations with a high prevalence of circulating MCL cells, bone marrow, and gastrointestinal involvement. MCL cells display a distinct immunophenotype with expression of CD5, CD19, CD20, CD22, but absence of CD23. The hallmark translocation t(11;14)(q13;q32) is another characteristic in MCL, bringing the cyclin D1 (BCL1/CCND1) gene under the control of the immunoglobulin heavy chain enhancer, and resulting in an overexpression of cyclin D1 3, 4 . Generally, MCL is considered an incurable disease, with a continuously decline in survival, resulting in a median overall survival (OS) of only 30 to 43 months, and less than 15% long-term survivors 5, 6 . New therapeutic modalities, in particular combinations of intensive polychemotherapy with monoclonal antibodies (Rituximab plus hyper-CVAD, R-CHOP) with or without autologous stem cell support improved remission rates, and are currently used in frontline treatment for younger MCL patients 7, 8 , but their impact on long-term patient outcome remains controversial. Despite the high partial remission and complete remission rates with these regimens, minimal residual disease (MRD) is common, leading to relapses in the majority of patients.
There is growing evidence suggesting that interactions between the neoplastic B cells and accessory cells in tissue microenvironments, such as the lymphatic tissues, are critical for disease progression in various B cell malignancies 9, 10 . Chemokine receptors and adhesion molecules are essential for normal and malignant B cell trafficking and homing to such tissue For personal use only. on . by guest www.bloodjournal.org From microenvironments, but their expression and function in MCL is largely unknown.
Because drugs targeting these molecules are currently in preclinical and clinical development 11 , we examined expression and function of chemokine receptors and adhesion molecules, and tested novel drugs targeting these molecules in primary MCL cells and MCL cell lines.
Normal B cell trafficking and function largely depend upon interactions between B cells and accessory cells collectively referred to as stromal cells 12, 13 .
For example, stromal cells in secondary lymphatic tissues constitutively express chemokines such as CXCL12 and CXCL13 that provide guidance for B cell positioning within distinct lymph node compartments 12, 14, 15 . According to the multistep paradigm, initially proposed by T. Springer 16 , lymphocyte trafficking and homing require the cooperation between chemokine receptors and adhesion molecules, such as integrins, CD44, and L-selectins. Lymphocytes actively enter and home into tissue microenvironments, such as the secondary lymphatic tissues, where stromal cell networks provide guidance by secreting chemokines, establishing chemokine gradients, and expressing ligands for lymphocyte adhesion molecules. Coordinated lymphocyte entry, migration, and territoriality are essential during immune surveillance and induction of specific immune responses 14, [17] [18] [19] . In B cell lymphomas/leukemias, the neoplastic B cells largely retain the capacity of their normal counterparts for trafficking and homing, as demonstrated in Chronic Lymphocytic Leukemia (CLL), B cell Acute Lymphoblastic Leukemia (ALL), and follicular lymphoma cells 20 , both in vitro 21, 22 and in vivo 23 . Moreover, studies in follicular lymphoma demonstrated that accessory cells in the lymphoma microenvironment that are not part of the malignant clone, such as CD68 + macrophages or T cells, have a major impact on the clinical outcome [24] [25] [26] , indicating that crosstalk between malignant B cells and stromal cells plays a key role in disease progression and/or resistance to The MCL cell lines SP-53, Mino, JeKo-1, and Granta-519 were cultured as previously described 22 .
MATERIALS AND METHODS
Cell purification, cell lines
Chemokines, antibodies, inhibitors and flow cytometry
Synthetic human CXCL12 (stromal cell derived factor-1, SDF-1α) was purchased from Upstate (Lake Placid, NY), CXCL13 (BCA-1) was purchased from R&D systems (Minneapolis, MN). The following mAbs specific for human surface antigens were used: anti-CXCR5-phycoerythrin (PE) from R&D systems, anti-CD5-fluorescein isothiocyanate (FITC), anti-CD44-FITC, anti-CD49d-PE, anti- with a pore size of 5 μm. Filters then were transferred to wells containing medium with or without CXCL12 or CXCL13. For inhibition experiments cells were preincubated for 1 hour with 100 μg/ml Plerixafor or 1 μg/ml pertussis toxin before they were added to the inserts. In an additional set of experiments to differentiate between chemotaxis and chemokinesis, CXCL12 or CXCL13 was added at the same concentrations to both, the top and lower chambers. The chambers were incubated for 3 hours at 37°C in 5% CO 2 . After this incubation the cells in the lower chamber were suspended and divided into aliquots for counting with FACSCalibur, as described 21 .
Actin polymerization
MCL cells were suspended in FACS buffer in concentration 1. cells were preincubated for 1 hour with 100 μg/ml Plerixafor or 1 μg/ml pertussis toxin, or 2, 5, 10 μg/ml Natalizumab before they were added to the wells. As a control antibody we used MOPC-21 at the concentration 200 μg/ml. We also performed pretreatment with 10 or 100 μg/ml small cyclic CS-1 peptide inhibitor or control scrambled peptide at the same concentrations. The plates then were incubated for 6 hours at 37°C in 5% CO 2 , after which supernatant cells were removed by washing. Stromal cell layers were photographed, then single cell suspensions were obtained by adding trypsin, and the migrated cell fraction was quantified by flow cytometry, as previously described 21 .
Cell viability testing
To 
Western blotting
For p44/p42 mitogen-activated protein kinase (MAPK) immunoblot assays 1×10 7 MCL cells were serum-starved for 2 hours, stimulated with CXCL12 at 250 ng/ml and CXCL13 at 1 μg/ml for different time points and then lysed. To investigate the role of blocking CXCR4 in signal transduction, cells were pretreated with 100 μg/ml Plerixafor for 1 hour and then stimulated with CXCL12.
Protein content was determined using the Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA) reagent. Equal amounts of protein were separated by SDS-PAGE and were transferred onto nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA). Western blot analysis was performed using the phospho-p44/42 (Thr202/Tyr204) rabbit polyclonal antibodies that specifically recognizes the phosphorylated form of p44/42, the p44/42 MAP kinase total antibodies, and β-actin (13E5) rabbit mAbs (all from Cell Signaling Technology, Danvers, MA). Immunoreactive bands were visualized using peroxidase-labelled goat-anti rabbit secondary antibody (Amersham, UK) and enhanced by using the ECL detection system (Amersham, GE Healthcare, UK).
Data analysis and statistics
Results are shown as mean plus or minus standard error of the mean (SEM) of at least 3 experiments each. For statistical comparison between groups, the Student paired T-test was used. Analyses were performed using GraphPad Prism 4 software for Macintosh. A p value of <0.05 was considered as statistically significant. Flow cytometry data were analyzed using the FlowJo software.
RESULTS
Expression of cell surface migration-related molecules on MCL B cells
We characterized the expression of adhesion molecules, such as CD44, VLA-4, and CD62L, as well as CXC chemokine receptors CXCR3, CXCR4 and CXCR5 in malignant B cells from lymphoma patients and cell lines. We found that MCL B cells from patients display high cell surface expression of CD44 and
CD49d, but not CD62L. As shown in Table 1 expression, whereas the level of CXCR4 expression was comparable (supplemental Table 1S ).
CXCL12 and CXCL13 induce actin polymerization in MCL cells
Reorganization of the actin cytoskeleton is an early event in the migratory response to chemokines. To evaluate the ability of CXCL12 and CXCL13 chemokines to induce changes in filamentous actin (F-actin), MCL cells were treated with 200 ng/ml CXCL12 and CXCL13. As shown in Figure 2A , stimulation with these chemokines induces a transient increase in F-actin that peaks 15 seconds after exposure to CXCL12 and CXCL13. Actin polymerization after CXCL12 stimulation was completely inhibited by preincubation of MCL cells for 1 hour with 100 μg/ml of the CXCR4 antagonist Plerixafor (Figure 2 A,B) or 1 μg/ml of pertussis toxin, indicating that this response can be blocked by these inhibitors and is mediated through pertussis-toxin sensitive G i proteins. (100 μg/ml) or pertussis toxin (1 μg/ml) to levels that were 5.2% (±3.3%) for 
Chemotaxis of MCL cells in response to
Plerixafor, Natalizumab, pertussis toxin, and CS-1 peptide inhibit spontaneous migration of MCL cell lines beneath stromal cells (pseudoemperipolesis)
In co-culture of MCL cells with M2-10B4 bone marrow stromal cells (MSC, Figure 3A ) we noticed high levels of spontaneous migration of MCL beneath the stromal cells ( Figure 3B ).
This striking phenomenon, called pseudoemperipolesis, was previously reported for CLL cells 21 and other leukemia cells 33 , and is characterized by the dark appearance of the cells that have migrated into the same focal plane as the stromal cells, whereas the more 92.2 ± 1.2% at 24 h, 88.2 ± 1.6% vs. 68.9 ± 4.3% at 48 h, and 87.8 ± 3.8% vs.
44.4 ± 3.8% at 72 h. Results are presented as the mean ± SEM relative to untreated controls. In MINO cells, this effect was more pronounced, as illustrated in Figure 4B . The mean viabilities for of MINO cells treated in the presence or absence of stromal cells were 92.6%±5.3% vs. 46.9 ± 7.3%, 89.8 ± 4.0% vs. 9.0 ± 2.8%, and 80.2 ± 6.7% vs. 7.5 ± 1.0%, respectively. Figure 4C) , and, as depicted in Figure 4D , this difference was significant at each time point. The mean viabilities for SP-53 cells were 100.0 ± 4.0% in the migrated vs. 62.1 ± 3.2% in the non-migrated fraction after 24 hours, 87.4 ± 2.3% vs. 66.4 ± 2.6% after 48 hours, and 87.2 ± 7.3% vs. 53 ± 6.4% after 72 hours, respectively. Results are presented as the mean ± SEM relative to untreated controls.
We also tested the cytotoxicity of 4-HC, the bioactive form of cyclophosphamide, in MCL co-cultures with M2-10B4. As illustrated in Figure 5A 28.8 ± 0.6% after 24 h and 72.4 ± 2.0% vs. 1.9 ± 0.1% after 48 h. Results are presented as the mean ± SEM relative to untreated controls.
CXCL12 and CXCL13 stimulate p44/p42 MAP-kinase activation in MCL cells
Transient activation of p44/p42 mitogen-activated protein (MAP)-kinase (ERK 1/2) is an inducible signaling pathway related to cell survival and growth. We found that MCL cells spontaneously migrate beneath MSC, and in vitro phenomenon termed "pseudoemperipolesis" 21, 33 was abundant in MCL (Fig. 3 ).
These data support the concept that MCL cells utilize chemokine receptors and adhesion molecules for trafficking and homing to tissue microenvironments, where stromal cells constitutively express respective ligands and provide supportive stromal niches for MCL cells.
Once MCL adhere to MSC, they are largely protected from the cytotoxic effect of F-ara-A and 4-HC (Fig. 4, 5) , and in particularly the MCL cell fraction that migrated beneath the MSC was almost completely protected, suggesting that stromal cell-mediated drug resistance is an important drug resistance mechanism in MCL. Collectively, these experiments support a model in which MCL cells reside in tissue microenvironments, such as the marrow and the secondary lymphatic tissues, where they are protected and nourished by MSC.
Hence, disruption of the heterotypic adhesion may liberate MCL from MSC niches and make them more accessible to conventional drugs. In order to test this hypothesis, we evaluated compounds that target both, CXCR4 chemokine receptors (Plerixafor, pertussis toxin), and VLA-4 integrins (Natalizumab, cyclic CS-1 peptides). We found that both Plerixafor and pertussis toxin can effectively inhibit activation of MCL cells in response to CXCL12 in chemotaxis and actin polymerization assays (Fig. 2) . Moreover, we noticed that pre-treatment with Natalizumab and cyclic CS-1 peptide was highly effective in inhibiting MCL cell migration beneath MSC (Fig. 3) . Interestingly, we noticed that in the pseudoemperipolesis assay blocking of CXCR4 with Plerixafor or pertussis toxin was less effective when compared to Natalizumab and cyclic CS-1 peptides. One possible explanation for these differences could be based upon the multistep model of cell migration 16 , which describes that adhesion molecules, such as VLA-4, are critical for the early phase of adhesion to MSC 33, 41 . Once this initial adhesion is established, chemokine receptor activation is responsible for later phases of adhesion and subsequent migration into tissues 16 or beneath MSC 9 .
As such, targeting VLA-4 might be more effective in blocking pseudoemperipolesis, because it targets the upstream early phase of heterotypic adhesion, whereas blocking of CXCR4, modulates later, downstream events.
Moreover, MCL cells display high levels of spontaneous migration that is independent from chemokine receptor activation and accounts for the high levels of spontaneous migration of the MCL cells (about 5% of input cells) towards chemotaxis chambers without chemokine ( Figure 2C ). Once adhesion to MSC is established via VLA-4, spontaneous, chemokine-independent MCL cell migration may be sufficient to drive migration of a significant proportion of the MCL cells beneath the MSC in the pseudoemperipolesis assay. However, it is questionable whether these in vitro effects would translate into differences in clinical application of these new agents. Currently, Plerixafor is used clinically for autologous stem cell mobilization in patients with lymphomas and MM, and early phase clinical trials of this drug in patients with leukemias (AML, CLL) are ongoing. In the later trials, the idea is to mobilize the leukemia cells from protective tissue microenvironments 42 . Both, Plerixafor 43, 44 , and Natalizumab 45, 46 have been demonstrated to be effective in mobilizing various hematopoietic cells from tissues to the blood. Based upon these clinical data with Plerixafor, it would
For personal use only. on March 31, 2017. by guest www.bloodjournal.org From be anticipated that targeting of CXCR4 in MCL patients could also mobilize MCL cells from protective tissue niches and thereby make them better accessible for cytotoxic therapy. A similar, or even more pronounced, effect would be anticipated for Natalizumab, based on the data presented in this study.
Stroma-mediated drug resistance, also called cell adhesion-mediated drug resistance (CAM-DR) 30 is a well-defined phenomenon demonstrated for CLL 31, 47 , acute leukemias 48, 49 and MM 30, 50 . In this study we demonstrated that marrow 
